TEL/AML1 fusion is not a prognostic factor in Dutch childhood acute lymphoblastic leukaemia [1]

British Journal of Haematology

Volumn 113, Issue 1, 2001, Pages 254-258

  Hubeek, I ^a   Ramakers van Woerden, N L ^a   Pieters, R ^b,c   Slater, R ^d,e   Beverloo, H B ^e   Van Wering, E R ^b   Kamps, W ^b,f   Hahlen K ^b,c   Veerman, A J P ^a,b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Dutch Childhood Leukaemia Study Group   (Netherlands)

^c SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^d ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Acute lymphoblastic leukaemia; Childhood; Prognosis; TEL AML1 gene fusion

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; CHILDHOOD CANCER; IMMUNOPHENOTYPING; LETTER; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR;

EID: 0035011937     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2001.02673.x     Document Type: Letter

References (6)

1. Incidence of TEL/AML1 fusion in children with relapsed acute lymphoblastic leukaemia
2. Acute lymphoblastic leukaemia
3. TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukaemia
4. TEL-AML1 fusion transcript in relapsed childhood acute lymphoblastic leukaemia
5. Prognostic significance of TEL/AML1 fusion transcript in childhood B-precursor acute lymphoblastic leukaemia
6. Childhood acute lymphoblastic leukaemia in the Netherlands - Randomized studies and nationwide treatment results from 1972 to 1995